Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
AIM The aim of this study was to compare the efficacy and safety of alpha1-adrenoceptor ( alpha1-AR ) antagonist monotherapy with combination therapy using alpha1-AR antagonist and anticholinergic agent for benign prostatic hyperplasia ( BPH ) with storage symptoms as the chief complaint . METHODS In this prospect i ve comparative study , either 25 - 75 mg/day of naftopidil monotherapy ( monotherapy group ) or combination therapy using 25 - 75 mg/day of naftopidil and an anticholinergic agent ( 10 - 20 mg/day of propiverine hydrochloride or 2 - 6 mg/day of oxybutynin hydrochloride ; cotherapy group ) were administered for 12 weeks to 101 BPH patients with storage symptoms . RESULTS International prostate symptom score ( IPSS ) and quality of life ( QOL ) index improved significantly in both groups , with no marked differences between groups . Maximum flow rate ( Qmax ) and residual urine volume ( RUV ) tended to improve in both groups , again with no marked differences between groups . However , median post-therapeutic RUV was significantly worse for the cotherapy group ( 45.0 mL ) than for the monotherapy group ( 13.5 mL ; P = 0.0210 ) . Ratio of patients with increased RUV was also significantly worse for cotherapy ( 22.9 % ) than for monotherapy ( 5.0 % ; P = 0.038 ) . CONCLUSIONS Although the anticholinergic dosage was low , the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent . Therefore , naftopidil is a useful agent as the first choice in BPH patients with storage symptoms
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .